Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3

Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor program Building on recent announcements, this collaboration with Accent

Related Keywords

Saclay ,France General ,France ,Qi Wang ,Hubei ,China ,Shanghai ,United States ,Wei Wang ,Gansu ,Paris ,Yin Dong ,Guangdong ,Cambridge ,Cambridgeshire ,United Kingdom ,Yong Li ,Guizhou ,American ,Jennifer Gordon ,Benjamind Wheeler ,Ipsen Euronext ,Christelle Huguet ,Zacharya Gurard Levin ,Oumin Shi ,Michaeld Scholle ,Shakti Narayan ,Jess Smith ,Quanxiang Zeng ,Roberta Copeland ,P Ann Boriack Sjodin ,Xiaoquin Lu ,Scott Ribich ,Jeffreyl Hirsch ,Shanem Buker ,Head Of Global Communications ,Head Of Research ,Early Development ,Spectrum Science Communications ,Business Development ,American Cancer Society ,Accent Therapeutics ,Senior Vice President ,External Innovation ,Chief Executive Officer ,Rare Disease ,Consumer Healthcare ,Total Sales ,Sponsored Leveli American Depositary Receipt ,French Autorit ,Des March ,Acute Myeloid ,Hematology Oncology ,Aprilw Case ,Mass Spectrometric Assay ,Investor Relations ,Relations Manager ,Science Communications ,Lipsen ,Odds ,Another ,Program ,Into ,Linical ,Ncology ,Pipeline ,Through ,Exclusive ,Orldwide ,Collaboration ,Ith ,Accent ,Herapeutics ,Targeting ,Modifying ,Protein ,Ettl3 ,